Custom LNA Price Options

BSI offer LNA oligos synthesis with different versatilities. LNA oligo can be order with a mixture of DNA, RNA, nucleic acid analogues and different synthesis backbone and modifications.

All LNA oligo synthesis include/are:

• NO Setup Fee
• Deprotected, Desalted and Ready to Use
• QC by Mass Spectrometry MALDI-TOF, HPLC or PAGE
• Guaranteed Yields and Turnaround

• Large-Scale LNA Synthesis, are now available from 10 micromoles up to two grams! Call Technical Support at 800-227-0627 or write to us at biosyn@biosyn.com for more information.
• Large-Scale LNA Synthesis, are now available from 10 micromoles up to two grams! Call Technical Support at 800-227-0627 or write to us at biosyn@biosyn.com for more information.

Unmodified LNA Purifications Pricing

• Guarantee is for 20 to 50 bases in length.. Shorter oligos may have fewer ODs.
• An additional 1-2 days of turnaround time is required for purifications.
• Click here for recommended purification and applications!

Unmodified LNA Purifications Yields

• Guarantee is for 20 to 50 bases in length.. Shorter oligos may have fewer ODs.
• An additional 1-2 days of turnaround time is required for purifications.
• Click here for recommended purification and applications!
  

Bio-Synthesis Inc. offers Custom LNA Synthesis

Custom BNA Synthesis

Custom BNA (Bridged Acid Synthesis), was first described by Wengel and co-workers in 1998 as a novel class of conformationally restricted oligonucleotide analogues. LNA is a bicyclic nucleic acid where a ribonucleoside is linked between the 2'-oxygen and the 4'-carbon atoms via a methylene unit was the earlier generation of cyclic nucleic acid.

Bridged nucleic acid 2',4'-BNA^NC (2'-O,4'-aminoethylene bridged nucleic acid) is a compound containing a six-member bridged structure with an N-O linkage. This novel nucleic acid analogue can be synthesized and incorporated into oligonucleotides. When compared to the earlier generation of LNA, BNA was found to possess:

• Higher binding affinity against an RNA complement
• Excellent single-mismatch discriminating power
• Enhanced RNA selective binding
• Stronger and more sequence selective triplex-forming characters
• Stronger nuclease resistance to endo and exo-nucleases, even higher than the S(p)-phosphorothioate analogue.

Oligonucleotides containing BNA exhibit unprecedented thermal stability towards complementary DNA and RNA2, which allows excellent mismatch discrimination. In fact, the high binding affinity of BNA oligos is recommended for use in any hybridization assay that requires high specificity and/or reproducibility such as

• Labeled probes
• In situ hybridization probe
• SNP genotyping
• DNA MicroArray expression analysis
• Allele Specific
• mRNA sample preparation
• Molecular Beacons and PCR primers

As a result of these significant characteristics, the use of BNA-modified oligos in antisense drug development is now coming under investigation4 and, recently, the therapeutic potential of BNA has been reviewed.5 BSI offers BNA Synthesis with great flexibility. For more information on custom BNA synthesis, call 800-227-0627 or write to us at biosyn@biosyn.com

• BNA Synthesis
• BNA Modification
• Dual Labeled Probes
• BNA Conjugations
• LNA Chimeras

• Deprotected, desalted and ready to use
• Multi-scale capacities
• Purification by PAGE or RP-HPLC upon request
• QC analysis by MALDI-TOF Mass spectrometry, HPLC, PAGE analysis
• Fast delivery with high throughput capacity

References:
(1a) A.A. Koshkin, S.K. Singh, P. Nielsen, V.K. Rajwanshi, R. Kumar, M. Meldgaard, C.E. Olsen, and J. Wengel, Tetrahedron,1998, 54, 3607-3630.
(1b) S.K. Singh, P. Nielsen, A.A. Koshkin, and J. Wengel, Chem. Comm., 1998, (4), 455-456.
(2) L. Kværnø and J. Wengel, Chem. Comm., 1999, (7), 657-658.
(3) P. Mouritzen, A.T. Nielsen, H.M. Pfundheller, Y. Choleva, L. Kongsbak, and S. Møller, Expert Review of Molecular Diagnostics, 2003, 3(1), 27-38.
(4a) J. Kurreck, E. Wyszko, C. Gillen, and V.A. Erdmann, Nucleic Acids Res., 2002, 30, 1911-1918.
(4b)H. Ørum and J. Wengel, Curr. Opinion in Mol. Therap., 2001, 3, 239-243.
(5a) M. Petersen and J. Wengel, Trends in Biotechnology, 2003, 21(2), 74-81.
(5b) D.A. Braasch, D.R. Corey, Biochemistry, 2002, 41, 4503-4510.